Table 2. Patients’ responses to EGFR-TKI re-challenge.
| Response | Sequence pattern | Total (n = 66) | |||
|---|---|---|---|---|---|
| G to G (n = 13) | E to E (n = 12) | G to E (n = 33) | E to G (n = 8) | ||
| CR (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| PR (%) | 2 (15.4) | 1 (8.3) | 0 (0) | 1 (12.5) | 4 (6.1) |
| SD (%) | 5 (38.5) | 5 (41.7) | 7 (21.2) | 5 (62.5) | 22 (33.3) |
| PD (%) | 6 (46.1) | 6 (50.0) | 26 (78.8) | 2 (25.0) | 40 (66.6) |
| DCR | 53.8% | 50.0% | 21.2% | 75.0% | 39.4% |
| ORR | 15.4% | 8.3% | 0.0% | 12.5% | 6.1% |
| Median PFS (95% CI) | 3.2 (2.0–4.4) | 2.7 (0.5–4.9) | 1.2 (0.8–1.6) | 2.9 (2.6–3.2) | 2.0 (1.3–2.7) |
| Median OS (95% CI) | 5.1 (2.2–8.0) | 8.8 (4.1–13.5) | 4.1 (2.4–5.8) | 9.6 (4.7–14.5) | 6.8 (4.7–8.9) |
CR, complete response. PR, partial response. SD, stable disease. PD, progression disease. DCR, disease control rate. ORR, objective response rate. PFS, progression-free survival. OS, overall survival. CI, confidence interval G, gefitinib. E, erlotinib.